At a Glance
- Acquirer: Eli Lilly
- Target: Kelonia Therapeutics
- Deal value: $3.25B upfront; up to $7B total
- Focus area: In vivo CAR-T for cancer
- Next steps: Close H2 2026
What happened?
Eli Lilly announced a definitive agreement on 20 April 2026 to acquire clinical-stage biotech Kelonia Therapeutics for $3.25 billion upfront, with up to $3.75 billion more in milestones tied to clinical, regulatory and commercial progress. The deal bolsters Lilly’s oncology portfolio with Kelonia’s in vivo CAR-T platform.
Why does it matter?
Kelonia’s lead KLN-1010 reprograms patients’ T-cells inside the body to target cancer — eliminating ex vivo cell extraction, chemotherapy preconditioning and manufacturing delays that limit current CAR-T scalability. Success could transform multiple myeloma treatment and expand to solid tumours, tapping a $240B oncology market amid Lilly’s aggressive M&A spree.
Who’s behind it?
Cambridge, MA-based Kelonia (formerly Stheric Bio, 2022 spinout) raised <$60M at ~$100M valuation. Lilly gains the full team and IP for genetic medicine, integrating with its oncology assets like Verzenio and Jaypirca.
How was it achieved?
KLN-1010 uses lipid nanoparticles for gene delivery, expressing CARs directly in vivo. Preclinical data showed tumour clearance without lymphodepletion; Phase 1 expected soon. Lilly’s premium (~20-30x prior valuation) reflects conviction in simplifying CAR-T economics before pivotal data.
What’s next?
Transaction expected to close H2 2026, pending antitrust review. Lilly will advance KLN-1010 into clinic for blood cancers, with platform expansion to solid tumours. Represents <1% of Lilly’s $830B market cap.
What are people saying?
Kelonia CEO: “Our in vivo approach could make CAR-T accessible to millions.” Analysts: “Lilly pays premium for early-stage bet on next-gen cell therapy scalability.”